UP!

AKRX $0.09   View long term graphs

Akorn Pharmaceuticals (NASDAQ: AKRX) is an American generic pharmaceuticals manufacturer based in Lake Forest, Illinois. It is a component of the NASDAQ Biotechnology Index.

John Kapoor is not the founder but is a major shareholder since the 1990s.

Akorn acquired rival Hi-Tech Pharmacal in 2013.

In June 2015, it was reported that a hacker was trying to sell an Akorn customer database of more than 50,000 records. Akorn commented that "Although much of the information acquired is publicly available, we are in the process of notifying our valued customers about this incident".

In April 2017, Akorn was acquired by Fresenius for $4.3 billion.


Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q2 2020 2020-08-03 Future report Set alerts
Q1 2020 2020-05-06 0.00 0.00
Q4 2019 2020-02-26 -0.07 -0.64
Q3 2019 2019-10-31 0.02 0.38
Q2 2019 2019-08-01 -0.02 -0.89
Q1 2019 2019-05-07 -0.10 -0.65
Q4 2018 2019-02-28 -0.29 -1.71
Q3 2018 2018-11-06 -0.06 -0.56
Q2 2018 2018-08-01 0.16 -0.70
Q1 2018 2018-05-02 0.06 -0.23

Ratings

2016-05-26 Reiterated Rating Leerink Swann Hold
2016-05-17 Reiterated Rating Guggenheim Buy $40.00
2016-05-17 Reiterated Rating RBC Capital Outperform $37.00
2016-05-17 Reiterated Rating Royal Bank Of Canada Outperform $37.00
2016-05-11 Reiterated Rating Jefferies Group Buy $35.00
2016-04-16 Reiterated Rating Leerink Swann Market Perform
2016-03-23 Reiterated Rating Leerink Swann Market Perform $24.00 to $28.00
2016-03-23 Lower Price Target Susquehanna Neutral $32.00 to $30.00
2016-03-23 Reiterated Rating Jefferies Group Buy $43.00 to $35.00
2016-03-23 Reiterated Rating William Blair Outperform $58.00 to $36.00
2016-03-23 Reiterated Rating Piper Jaffray Hold
2016-03-23 Reiterated Rating Piper Jaffray Cos. Hold
2016-03-22 Lower Price Target S&P Equity Research $25.98 to $21.97
2016-03-22 Reiterated Rating Guggenheim Buy $40.00
2016-03-22 Reiterated Rating Craig Hallum Buy
2016-03-21 Lower Price Target Raymond James $53.00 to $30.00
2016-03-21 Lower Price Target Nomura Buy $46.00 to $42.00
2016-03-21 Lower Price Target Raymond James Financial Inc. $53.00 to $30.00
2016-03-21 Lower Price Target Nomura Holdings Inc. Buy $46.00 to $42.00
2016-03-18 Lower Price Target Deutsche Bank Buy $40.00 to $33.00
2016-03-18 Lower Price Target Deutsche Bank AG Buy $40.00 to $33.00
2016-03-16 Reiterated Rating Leerink Swann Market Perform $41.00 to $24.00
2016-03-14 Lower Price Target JPMorgan Chase & Co. Overweight $50.00 to $45.00
2016-02-25 Reiterated Rating Nomura Buy $46.00
2016-02-13 Reiterated Rating RBC Capital Buy
2016-02-12 Lower Price Target RBC Capital Outperform $52.00 to $37.00
2016-02-01 Reiterated Rating Guggenheim Buy $60.00
2016-01-30 Reiterated Rating RBC Capital Outperform $52.00
2016-01-28 Reiterated Rating Nomura Buy $46.00
2016-01-15 Reiterated Rating Craig Hallum Buy
2016-01-14 Reiterated Rating Nomura Buy $46.00
2016-01-13 Reiterated Rating Deutsche Bank Buy $40.00
2016-01-13 Reiterated Rating RBC Capital Outperform $52.00
2015-12-15 Reiterated Rating JPMorgan Chase & Co. Buy
2015-12-02 Upgrade Nomura Neutral to Buy $44.00 to $46.00
2015-11-06 Reiterated Rating RBC Capital Outperform $65.00 to $52.00
2015-11-06 Lower Price Target Jefferies Group Buy $56.00 to $43.00
2015-09-29 Initiated Coverage Nomura Neutral $44.00
2015-09-25 Reiterated Rating Leerink Swann Market Perform $50.00 to $41.00
2015-09-09 Initiated Coverage JMP Securities Market Perform
2015-07-20 Initiated Coverage Susquehanna Neutral $48.00
2015-06-03 Initiated Coverage Raymond James Outperform $53.00
2015-05-03 Reiterated Rating William Blair Outperform $58.00
2015-04-27 Reiterated Rating Deutsche Bank Buy
2015-04-27 Downgrade Piper Jaffray Overweight to Neutral $66.00 to $53.00
2015-04-20 Set Price Target Jefferies Group Buy $56.00
2015-04-15 Initiated Coverage JPMorgan Chase & Co. Overweight $61.00
2015-04-07 Initiated Coverage Deutsche Bank Buy $55.00
2015-03-27 Initiated Coverage Avondale Partners Outperform $56.00
2015-03-10 Reiterated Rating Jefferies Group Buy $59.00 to $56.00
2015-02-27 Downgrade Needham & Company LLC Buy to Hold
2015-02-27 Boost Price Target Leerink Swann Market Perform $42.00 to $55.00
2015-02-27 Reiterated Rating Jefferies Group Buy $49.00 to $50.00
2015-02-27 Boost Price Target WallachBeth Capital Buy $43.00 to $65.00
2015-02-26 Set Price Target Guggenheim Buy $60.00
2015-02-04 Initiated Coverage Sterne Agee CRT Buy $52.00
2015-01-26 Boost Price Target Piper Jaffray Overweight $45.00 to $55.00
2015-01-20 Boost Price Target Jefferies Group Buy $44.00 to $49.00
2014-12-09 Initiated Coverage William Blair Average to Outperform $50.00
2014-11-13 Upgrade CRT Capital Fair Value to Buy $46.00
2014-10-29 Initiated Coverage CRT Capital Fair Value $46.00
2014-10-14 Initiated WallachBeth Buy $43
2014-10-14 Initiated Coverage WallachBeth Capital Buy $43.00
2014-09-29 Upgrade RBC Capital Sector Perform to Outperform $36.00 to $45.00
2014-09-04 Boost Price Target Leerink Swann $26.00 to $40.00
2014-08-06 Boost Price Target Jefferies Group $31.00 to $40.00
2014-08-06 Boost Price Target Piper Jaffray Overweight $33.00 to $45.00
2014-08-06 Boost Price Target RBC Capital Sector Perform $26.00 to $36.00
2014-07-01 Boost Price Target Needham & Company LLC $30.00 to $36.50
2014-06-05 Reiterated Rating Bank of America Buy $33.00 to $28.00
2014-06-02 Initiated Coverage Goldman Sachs Neutral $27.00
2014-05-15 Reiterated Rating Jefferies Group Buy $28.00
2014-05-13 Reiterated Needham Buy $28 to $30
2014-05-13 Boost Price Target Needham & Company LLC Buy $28.00 to $30.00
2014-05-13 Boost Price Target Guggenheim Buy $30.00 to $33.00
2014-05-07 Reiterated Rating Jefferies Group Buy $28.00
2014-04-29 Reiterated Rating Jefferies Group Buy $28.00
2014-04-21 Initiated Coverage Jefferies Group Buy $28.00
2014-03-04 Reiterated Needham Buy $25 to $28
2014-03-04 Boost Price Target Needham & Company LLC Buy $25.00 to $28.00
2014-01-08 Downgrade Leerink Swann Outperform to Market Perform
2014-01-07 Initiated Coverage RBC Capital Sector Perform to Sector Perform $27.00
2013-11-18 Boost Price Target Needham & Company LLC Buy $23.00 to $25.00
2013-11-06 Boost Price Target Needham & Company LLC Buy $22.00 to $23.00
2013-10-07 Initiated Coverage Ned Davis Research Neutral
2013-09-26 Initiated Coverage Guggenheim Buy
2013-08-28 Reiterated Needham Buy $18 to $22
2013-08-07 Reiterated Needham Buy $16 to $18
2013-01-28 Initiated RBC Capital Mkts Sector Perform $14
2012-07-23 Downgrade Deutsche Bank Buy to Hold $15 to $14
2012-02-23 Reiterated Deutsche Bank Buy $13 to $15
2012-01-18 Reiterated Needham Buy $12 to $13
2011-12-23 Reiterated Deutsche Bank Buy $11 to $13
2011-09-16 Initiated Deutsche Bank Buy $11
2010-11-08 Reiterated Rodman & Renshaw Mkt Outperform $5 to $8
2010-07-15 Initiated Rodman & Renshaw Mkt Outperform $5
2009-02-26 Reiterated Credit Suisse Outperform $6 to $3
2007-03-27 Reiterated Friedman Billings Outperform $7.50 to $8.50
2016-05-26 Reiterated Rating Leerink Swann Hold
2016-05-17 Reiterated Rating Guggenheim Buy $40.00
2016-05-17 Reiterated Rating RBC Capital Outperform $37.00
2016-05-17 Reiterated Rating Royal Bank Of Canada Outperform $37.00
2016-05-11 Reiterated Rating Jefferies Group Buy $35.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In AKRX 0 funds of 2186 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
BONACCORSI JOSEPH Sr. VP and General Counsel 0.50%  (523546) AKRX /
KAPOOR JOHN N 0.49%  (505987) AKRX / INSY /
RAI RAJAT CEO 0.42%  (439738) AKRX /
KUTINSKY BRUCE COO, US Operations 0.32%  (333246) AKRX /
Silverberg Mark M Exec VP, Ops & Global Quality 0.25%  (256522) AKRX /
Dick Timothy A Chief Financial Officer 0.24%  (246311) AKRX /
JOHNSON RONALD M 0.15%  (156203) AKRX /
MEYER STEVEN J 0.10%  (107394) AKRX / INSY /
Portwood Duane A Executive Vice President & CFO 0.09%  (97696) AKRX /
WEINSTEIN ALAN D 0.08%  (80795) ADGE / AKRX /
Tambi Brian 0.06%  (65264) AKRX / INSY /
Graves Adrienne L 0.05%  (46938) AKRX / TEAR /
Kafer Jonathan EVP, Sales and Marketing 0.04%  (44324) AKRX /
Sabat John R Senior VP, National Accounts 0.04%  (40256) AKRX /
ABRAMOWITZ KENNETH 0.04%  (39782) AKRX /
Lichter Steven EVP, Pharmaceutical Operations 0.03%  (31106) AKRX /
Pollard Randall E. CAO & Interim CFO 0.03%  (28187) AKRX /
RAPPUHN TERRY ALLISON 0.03%  (27438) AKRX / QHC / SKH / SPAN /

Comments